HD-OPM Archive

What optimal treatment looks like: an aggressive prevention protocol

A plain-language tour of what a comprehensive, aggressive prevention protocol includes (the Bale-Doneen approach, very low LDL, blood pressure, inflammation, metabolic drugs, exercise and imaging), what the evidence shows for each piece, and where it remains unproven.

15 min read48 group posts cited53 studies discussed5 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • The Bale-Doneen protocol combines lifestyle counseling, regular imaging and biomarker testing, statin-based lipid control with ezetimibe or niacin, systolic blood pressure under 120, low-dose aspirin for high-risk people, insulin sensitizers and anti-inflammatories; in a 2016 community clinic cohort, maximum carotid wall thickness fell 52.7% at 2 years.
  • In the 2026 FLOWPROMOTE trial of 104 statin-naive people, LDL near 42.5 mg/dL (rosuvastatin 40 mg plus ezetimibe 10 mg) shrank total plaque 21.1% in 18 months versus 13.6% at LDL near 69.5 mg/dL.
  • A 2025 review cites guideline LDL targets of under 55 mg/dL for very-high-risk patients (under 40 after a recurrent event), yet fewer than one in four high-risk patients reach them.
  • Lowering LDL is not a cure: residual risk persists in every trial, and Louis Nervegna argues age is the largest single risk factor, so the group's philosophy is to target every modifiable factor.
  • Several attractive ideas remain unproven for heart attacks and strokes, including PCSK9 inhibitors as a monotherapy and Lp(a)-lowering drugs.
In this summary
  1. The Bale-Doneen protocol as a template
  2. The philosophy: target every risk factor, because age dominates
  3. Pillar one: very low LDL and plaque regression
  4. Pillar two: blood pressure
  5. Pillar three: inflammation and Lp(a)
  6. Pillar four: metabolic health and weight
  7. Pillar five: exercise and diet
  8. Pillar six: imaging and monitoring
  9. Nuances and cautions
  10. What this means for you
  11. Frequently asked questions
  12. The evidence behind this summary

When people in this group ask what "optimal" treatment looks like, they usually mean a protocol that goes beyond treating a single number. The answer that emerges from the group's posts is a layered strategy: measure the disease (not just the risk factors), push LDL cholesterol and ApoB very low, control blood pressure, address inflammation and metabolic health, exercise, and keep monitoring so the plan can be adjusted. The best-known written example is the approach of Drs. Brad Bale and Amy Doneen.1

The group's two admins, Louis Nervegna and Gokhan Can, return to the same philosophy repeatedly: nobody has settled which risk factor matters most, so the rational approach is to target all of them as aggressively as is safe, using diet, exercise, supplements and drugs together.2 Louis also frames modern heart disease as something that "used to be a terminal disease" and is now "a manageable chronic disease, if treated aggressively."3

This article is a summary of group discussion and the studies the posts cite. It is not medical advice. Many items below are admin opinions or small studies, and they are labelled as such; the admins consistently suggest discussing any change with your own cardiologist.

52.7%drop in maximum carotid wall thickness at 2 years in a Bale-Doneen clinic cohort1
21.1%less total coronary plaque in 18 months at LDL near 42.5 mg/dL in FLOWPROMOTE4
Under 55mg/dL LDL target for very-high-risk patients; fewer than one in four reach it5
19.5×higher risk of coronary death from simply ageing from 65 to 856

The Bale-Doneen protocol as a template

Gokhan summarized the methodology from a 2016 paper under the heading "What does an Optimal Treatment look like?" The components were:1

  • Lifestyle. Extensive behavioral, dietary and lifestyle counseling in keeping with accepted guideline practice.
  • Regular testing. Clinicians review laboratory data and CAC (coronary artery calcium) and CIMT (carotid intima-media thickness) imaging, with markers such as inflammation and fasting insulin tested regularly.
  • Lipid control. A statin, a statin plus niacin, a statin plus ezetimibe, or all three; people who could not tolerate statins received ezetimibe plus niacin. Fibrates, bile acid sequestrants and fish oils were added as needed to reach more aggressive lipid goals.
  • Blood pressure. A systolic target below 120, ideally using an ACE inhibitor, with other classes (angiotensin receptor blockers, beta-blockers, diuretics and others) used as indicated.
  • Antiplatelet therapy. Low-dose aspirin for secondary prevention and other high-risk individuals.
  • Insulin sensitizers. Metformin and pioglitazone for people with insulin resistance, metabolic syndrome or diabetes.
  • Anti-inflammatories. Colchicine (already FDA approved for secondary prevention) and possibly other agents such as high-dose omega-3.
  • Supplements that might help with longevity or avoid deficiencies.

Gokhan adds one 2023 update in his own words: semaglutide or tirzepatide for weight loss if behavioral counseling fails.1

What the paper found

The cohort came from a community prevention clinic. The median time to the last carotid imaging was 3.0 years. At 2 years, maximum carotid wall thickness had fallen 52.7% and mean thickness 3.0% (the gap between max and mean fell 87.0%), and lipid-rich plaque decreased 78.4% in the first 2 years, with further but slower declines afterward.1 Keep in mind these are imaging results from an observational clinic cohort, not a randomized comparison and not a count of heart attacks.

Carotid plaque shrank on the Bale-Doneen protocolPercent reduction at 2 years in a 2016 community prevention clinic cohort
Lipid-rich plaque−78.4%
Maximum carotid wall thickness−52.7%
Mean carotid wall thickness−3.0%
Observational imaging results with no control group; not a count of heart attacks or strokes. Source: 1
Show data
Value
Lipid-rich plaque−78.4%
Maximum carotid wall thickness−52.7%
Mean carotid wall thickness−3.0%

The philosophy: target every risk factor, because age dominates

Several posts explain why the group favors breadth. Louis shared a graphic of 17 modifiable risk factors and noted some are far better proven than others, but suggested targeting as many as possible.9 He also argues that LDL or ApoB lowering is not a cure: in every randomized trial considerable residual risk remained, however low LDL went, and it appeared higher in older people. Other contributors he lists include family history, blood pressure, smoking, excess weight, chronic inflammation, poor diet, inactivity and insulin resistance or diabetes.7

To illustrate how large aging is, he compared hazard ratios from the SCORE O.P. model for people over 65: each year of age multiplies risk by about 1.16, which compounds to roughly 19.5 times higher coronary death risk between 65 and 85, versus 2.3 times for diabetes and 1.88 times for smoking.6 He concludes that aging is more than 10 times bigger than any other single factor, which is why he argues against ranking the others.27

Age dwarfs every other single risk factorHow many times higher the risk of coronary death is, SCORE O.P. model for people over 65 (figures for women)
Ageing from 65 to 8519.5×
Diabetes2.3×
Smoking1.88×
The age figure is Louis's compounding of a hazard ratio of 1.16 per year over 20 years; the others are single hazard ratios from the same table. Source: 6
Show data
Value
Ageing from 65 to 8519.5×
Diabetes2.3×
Smoking1.88×
The SCORE O.P. table of hazard ratios Louis worked from: blood pressure, cholesterol, HDL, smoking, diabetes and each year of age, for women and men, for coronary and other cardiovascular death.
The SCORE O.P. table of hazard ratios Louis worked from: blood pressure, cholesterol, HDL, smoking, diabetes and each year of age, for women and men, for coronary and other cardiovascular death.6

Evidence that treatment works at the population level is also offered. Louis shares WHO data showing US heart disease deaths falling from over 500 per 100,000 in 1950 to almost 100 in 2020, and attributes the drop mainly to better treatments such as medications, achieved despite rising obesity.310 He says the decline reflects fewer heart attacks and strokes, not merely better survival, and that age-adjusting the numbers matters because life expectancy rose from 68 to 79 years over the period.1112

WHO data charted by Our World in Data: the age-standardized US death rate from cardiovascular disease fell from over 500 per 100,000 in 1950 to almost 100 in 2020, a far steeper fall than for any other cause.
WHO data charted by Our World in Data: the age-standardized US death rate from cardiovascular disease fell from over 500 per 100,000 in 1950 to almost 100 in 2020, a far steeper fall than for any other cause.3

Pillar one: very low LDL and plaque regression

Targets

Gokhan summarized a July 2025 review, "Pushing the limits of LDL cholesterol." It reports guideline targets of under 55 mg/dL for very high-risk patients and under 40 mg/dL after a recurrent event, PCSK9 inhibitors adding a 59-62% LDL reduction on top of statins, and the FOURIER trial's 15% reduction in primary events at a median LDL of 30 mg/dL. A meta-analysis cited there found a 21% relative risk reduction for every 38.7 mg/dL (1 mmol/L) drop, with benefit down to 21 mg/dL. The review concludes that fears about hemorrhagic stroke, cognitive decline or hormone disruption are unsupported, and that fewer than one in four high-risk patients reach the target.5

A 2019 JACC review that Gokhan summarized adds the plaque rationale. It reports that in the PROSPECT study culprit lesions grew from 32% to 65% stenosis before events, that progression stops at LDL below 70 mg/dL, and that regression generally needs LDL below 60 mg/dL.13

The 2019 JACC review's central illustration: instead of waiting for a first event, detect subclinical atherosclerosis by imaging and treat it as secondary prevention, aiming to halt plaque progression.
The 2019 JACC review's central illustration: instead of waiting for a first event, detect subclinical atherosclerosis by imaging and treat it as secondary prevention, aiming to halt plaque progression.13

What statins do to plaque

Louis has posted many studies under a "statin reverse" theme. The core claims:

  • Six large randomized trials showed statins reduce total plaque volume 5% to 17% within a few years; he lists COSMOS (~5%), SATURN (~5.5%), ASTEROID (~6.5%), IBIS-4 (~7.5%), STABLE (~8%) and JAPAN-ACS (~17%).14
  • A Cleveland Clinic cardiologist explains the reversal comes mainly from shrinking the cholesterol-rich lipid core, which also stabilizes plaque; up to 24% of plaque volume can reverse when LDL is pushed below 70 mg/dL.15
  • In JAPAN-ACS (over 300 patients with acute coronary syndrome at 33 centers), pitavastatin 4 mg and atorvastatin 20 mg reduced plaque volume 16.9% and 18.1% over 8 to 12 months.16
  • The YELLOW study, using near-infrared spectroscopy and ultrasound, found lipid-core burden fell within 7 to 8 weeks of intensive rosuvastatin, stabilizing plaque rather than shrinking blockages; YELLOW III added the PCSK9 inhibitor evolocumab for greater improvement.17
  • Statins also thicken the fibrous cap: a meta-analysis found an average gain of roughly 59 micrometers, and the EASY-FIT study saw 69% thickening on atorvastatin 20 mg versus 17% on 5 mg.18
  • One case report documented a severe LAD blockage becoming mild over 4 years on 10 mg atorvastatin. Louis stresses this was an outlier, not what everyone should expect.19
Statins shrank plaque in six large trialsApproximate reduction in total plaque volume within a few years, as listed by Louis
COSMOS~5%
SATURN~5.5%
ASTEROID~6.5%
IBIS-4~7.5%
STABLE~8%
JAPAN-ACS~17%
Different trials, drugs, doses, imaging methods and durations, so the bars are not a head-to-head comparison. Source: 14
Show data
Value
COSMOS~5%
SATURN~5.5%
ASTEROID~6.5%
IBIS-4~7.5%
STABLE~8%
JAPAN-ACS~17%

FLOWPROMOTE: lower LDL, more regression

The newest trial the group discusses is FLOWPROMOTE (JAMA Cardiology, 2026), in 104 statin-naive adults in Denmark with stable coronary disease, scanned by CT angiography at baseline, 9 and 18 months.20 One arm received atorvastatin 40 mg, the other rosuvastatin 40 mg plus ezetimibe 10 mg. LDL reached 69.5 versus 42.5 mg/dL; total plaque volume fell 13.6% versus 21.1%, and non-calcified (soft) plaque fell 20.0% versus 28.2%.421 Louis notes lower achieved LDL was linearly associated with more regression, which he reads as supporting LDL as causal.14

FLOWPROMOTE: lower LDL, more plaque regressionPercent reduction in coronary plaque volume over 18 months, 104 statin-naive adults with stable coronary disease
Rosuvastatin 40 + ezetimibe 10 (LDL 42.5)Atorvastatin 40 (LDL 69.5)
Total plaque volume21.1%13.6%
Non-calcified (soft) plaque28.2%20.0%
Imaging endpoint only; calcified plaque increased in both groups and heart attacks were not measured. Source: 42122
Show data
Rosuvastatin 40 + ezetimibe 10 (LDL 42.5)Atorvastatin 40 (LDL 69.5)
Total plaque volume21.1%13.6%
Non-calcified (soft) plaque28.2%20.0%

Caveats noted in a shared write-up: the benefit was mainly in soft plaque, calcified plaque actually increased in both groups, and the trial measured imaging rather than heart attacks.22 Louis also cites a 2023 meta-analysis linking each 1-point drop in percent atheroma volume to about 19% lower odds of major cardiac events.4

Adding ezetimibe and PCSK9 inhibitors

  • A meta-analysis of 15 trials (123,785 patients) of add-on lipid lowering (ezetimibe, bempedoic acid or PCSK9 inhibitors) found 19% fewer cardiovascular events than statins alone, but no improvement in all-cause mortality (odds ratio 0.99). A Canadian primary prevention cohort of 67,884 people found combination therapy beat high-intensity statin for all-cause death (HR 0.85) and stroke (HR 0.86), but not heart attack. Gokhan's digest also notes that in 264 STEMI patients, rosuvastatin 40 mg plus ezetimibe reached LDL below 55 in 90% versus 47.9% on rosuvastatin alone.23
  • A 47-person uncontrolled study of evolocumab (Repatha) with average LDL near 30 mg/dL found non-calcified plaque fell from 607.3 to 562.1 microliters over 18 months while total plaque was unchanged. 37 of 47 had some soft plaque regression.24 Louis cautions that PCSK9 inhibitors have not yet been rigorously proven to reduce heart attacks and strokes as a monotherapy and that this study had no control group.8
  • Alirocumab added to moderate statins in 61 patients limited calcium progression to a median of +2.9% versus +10.6% over 18 months.2526

Choosing a statin and side-effect questions

Louis shares a comparison in which both atorvastatin 40-80 mg and rosuvastatin 20-40 mg typically lower LDL by 50% or more; rosuvastatin is more potent per milligram, but in the randomized LODESTAR trial 3-year clinical outcomes did not differ significantly.27

On safety, Gokhan shared a review concluding that statins modestly raise new-onset diabetes in a dose-dependent way, mostly in people with existing metabolic risk factors (JUPITER saw a 26-27% increase alongside a 44% cut in major events), and that ezetimibe, PCSK9 inhibitors and pitavastatin are options that limit glycemic harm.28 Meta-analyses of randomized trials found no increase or decrease in cancer from statins.2930 Louis's argument that statins mildly stress mitochondria and activate AMPK is his own interpretation built on a 2006 laboratory study.31

The calcium paradox

A frequent source of alarm is a calcium score that rises on treatment. A review Gokhan shared argues that statins reduce events and soft plaque but do not slow Agatston score progression, citing the St. Francis trial (events down 33% with no CAC change), SALTIRE (progression 26% versus 18% on placebo) and a cohort where the odds of severe calcification rose to 4.48 after more than 10 years of statin use. It interprets this as plaque turning into stable scar.32 Louis recommends Gokhan's article on why a calcium score can rise as the heart gets healthier, noting that a score above 400 suggests significant risk.33 This interpretation is debated, so ask your cardiologist how to read your own trend.

Pillar two: blood pressure

Bale-Doneen aims for a systolic pressure under 120.1 Louis says the AHA lowered the definition of high blood pressure because several very large randomized trials showed that aggressively treating it early greatly reduces long-term heart attack and stroke risk.34

Pillar three: inflammation and Lp(a)

Inflammation is a more contested pillar. In a debate summarized by Gokhan, Peter Libby argued for substantial residual inflammatory risk even with LDL controlled, while Derick Raal argued LDL is the primary cause and inflammation largely a consequence; both agreed that addressing lipids and inflammation has value.35 Louis notes statins, especially combined with ezetimibe, lower Lp-PLA2, a marker of inflammation inside plaque.36

Lp(a) is a cautionary tale about markers. Lp(a)HORIZON, testing pelacarsen in people with prior heart attack, stroke or peripheral disease, missed its primary endpoint; participants were already aggressively treated.37 Louis floats a theory that high-intensity statins, used by 78% of participants, may already neutralize the oxidized phospholipids Lp(a) carries, but the supporting data is a laboratory study.38

Pillar four: metabolic health and weight

The Bale-Doneen protocol includes metformin and pioglitazone for insulin resistance.1 A meta-analysis Louis summarized (25 trials, 109,846 patients) found GLP-1 agonists cut heart attack 14%, cardiovascular death 13%, major cardiac events 13% and stroke 12% over about 3.5 years, on top of statins and blood pressure drugs, with larger effects at higher BMI and with gastrointestinal side effects common. Louis adds his view that these drugs work through calorie restriction, so similar benefit might come from sustained weight loss.39

GLP-1 drugs cut events on top of standard carePercent risk reduction versus placebo, meta-analysis of 25 randomized trials (109,846 patients), about 3.5 years
Heart attack−14%
Cardiovascular death−13%
Major cardiac events−13%
Stroke−12%
Both groups were already on drugs such as statins and blood pressure medication. Gastrointestinal side effects were common. Source: 39
Show data
Value
Heart attack−14%
Cardiovascular death−13%
Major cardiac events−13%
Stroke−12%

Gokhan also shared an Attia article reporting that liver disease and type 2 diabetes together have a multiplicative effect on cardiovascular risk.40

Pillar five: exercise and diet

A shared review states regular moderate-to-high intensity exercise reduces coronary plaque burden, that exercise combined with LDL below 70 mg/dL is additive, and that extremely high volumes may increase calcification while producing more stable plaque.41 Louis also reshared a trial by Benjamin Levine in which sedentary 50-year-olds training 5-6 hours per week for two years made their hearts structurally younger, using Norwegian 4x4 intervals plus endurance and strength sessions.42

On diet, Louis summarized DISCO-CT: a DASH diet plus statins produced a 39.5 mm3 soft plaque reduction (adjusted to 52 weeks), which he equates to about 8 years of typical progression of roughly 5 mm3 per year.43

Pillar six: imaging and monitoring

An aggressive protocol assumes you can see the disease. Louis predicts coronary CT angiography will become standard in preventive cardiology, quoting a review that total plaque burden and non-calcified plaque often outperform stenosis in predicting events.44 Without imaging, Bale-Doneen relied on CAC and carotid measurements.1

Nuances and cautions

  • Observational and single-person results. Charles Grashow's account of reversing his calcium trajectory with an intensive regimen (LDL target 30 mg/dL, hsCRP 0.5, high-dose nattokinase) is explicitly a one-person story, not a trial.45
  • Low LDL and mortality. Louis explains that low LDL correlating with higher mortality in cancer reflects reverse causality, since tumors scavenge LDL.46
  • Keto and very high LDL. Louis relays a critique that the LMHR study enrolled only extremely healthy people with no atherosclerosis and so could not detect progression.47 In the Keto-CTA analysis he quotes, the median non-calcified plaque increase was 18.8 mm3 over a year, versus 7 mm3 predicted.48
  • Surrogate endpoints. Plaque imaging is not the same as fewer heart attacks, and several add-ons lack outcome proof.823

What this means for you

  • The group's admins suggest asking your cardiologist which pieces of the protocol (lipids, blood pressure, glucose, inflammation, imaging) are covered in your plan.1
  • Many posts discuss LDL goals under 70 and sometimes under 55 mg/dL; discuss your own target with your doctor.513
  • Consider how you will track progress, whether CAC, CT angiography, ApoB or hsCRP, and interpret rising calcium with a clinician.3244
  • Treat exercise, diet and weight as parts of the protocol rather than substitutes for it.4143
  • Be cautious with markers and add-ons that lack event data; lowering Lp(a) with pelacarsen did not meet its primary endpoint in HORIZON.37

Frequently asked questions

Does an aggressive protocol cure heart disease?

No. Louis stresses residual risk remains in every randomized trial and age is the largest factor.7

How low should LDL go?

A 2025 review cites targets under 55 mg/dL for very-high-risk patients, and under 40 after a recurrent event.5

Can plaque really shrink?

Randomized trials cited in the group show total plaque shrinking 5% to 21% over 18 months to a few years with intensive lipid lowering.414

Is rosuvastatin better than atorvastatin?

Rosuvastatin is more potent per milligram, but outcomes in LODESTAR did not differ significantly.27

Why can my calcium score rise on treatment?

One review argues statins convert soft plaque into stable calcified scar.3233

Does blood pressure belong in the protocol?

Yes: the Bale-Doneen approach aims for a systolic pressure below 120.1

The evidence behind this summary53 studies · 9 meta-analyses · 17 trials · 11 observational

The 48 group posts cited above discuss 53 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 9Randomized trials 17Observational studies 11Reviews & guidelines 5Animal & lab studies 3Other sources 8

Strongest evidence discussed

All 53 studies and sources
Sources from the group (48)
  1. Bale-Doneen protocol: aggressive multi-drug risk management reduced carotid IMT Gokhan Can · Dec 03, 2023 · Facebook
  2. Aging is the biggest heart disease risk factor, so target all risk factors aggressively Louis Nervegna · Sep 20, 2025 · Facebook
  3. US heart disease death rate fell about 5-fold since 1950, from 500+ to ~100 per 100,000 Louis Nervegna · Jul 12, 2025 · Facebook
  4. FLOWPROMOTE: rosuvastatin plus ezetimibe shrank total coronary plaque 21% in 18 months Louis Nervegna · Nov 14, 2026 · Facebook
  5. Review: aggressive LDL lowering outweighs theoretical risks, yet few reach <55 mg/dL Gokhan Can · Oct 28, 2025 · Facebook
  6. Age raises CVD death risk about 19.5x from 65 to 85, far above diabetes or smoking Louis Nervegna · Dec 18, 2023 · Facebook
  7. Lowering LDL or ApoB is no cure: residual risk persists in every trial; age matters most Louis Nervegna · Aug 20, 2024 · Facebook
  8. Repatha alone reversed soft plaque in 37 of 47 patients over 18 months at LDL near 30 Louis Nervegna · Nov 13, 2026 · Facebook
  9. Seventeen modifiable heart-disease risk factors: target as many as possible Louis Nervegna · Nov 23, 2023 · Facebook
  10. Heart disease deaths fell ~5x since 1950 mainly from better treatments despite obesity Louis Nervegna · Aug 30, 2024 · Facebook
  11. US heart disease deaths fell ~70% since the 1950s, mainly from fewer heart attacks Louis Nervegna · Nov 13, 2024 · Facebook
  12. US age-adjusted CVD death rates fell almost fivefold from 1950 to 2019 Louis Nervegna · Apr 22, 2026 · Facebook
  13. JACC review: rapid plaque progression precedes rupture and LDL below 70 mg/dL halts it Gokhan Can · Jan 02, 2026 · Facebook
  14. FLOWPROMOTE: lower achieved LDL gave more plaque regression, 21.1% at LDL near 43 Louis Nervegna · Oct 31, 2026 · Facebook
  15. Statins reverse total and soft plaque once LDL is below 70 mg/dL, Cleveland Clinic says Louis Nervegna · Sep 04, 2025 · Facebook
  16. Japan-ACS: modest statin doses cut non-culprit plaque volume by about 17-18% Louis Nervegna · Sep 18, 2025 · Facebook
  17. YELLOW trials: intensive rosuvastatin cut lipid-core plaque within 7-8 weeks Louis Nervegna · Aug 15, 2026 · Facebook
  18. Statins also thicken the fibrous cap of plaques, shown by OCT studies Louis Nervegna · Apr 29, 2026 · Facebook
  19. Case report: 10 mg atorvastatin cleared most of a severe LAD blockage over 4 years Louis Nervegna · Oct 06, 2025 · Facebook
  20. FLOWPROMOTE: rosuvastatin plus ezetimibe vs atorvastatin for plaque regression Louis Nervegna · Nov 07, 2026 · Facebook
  21. FLOWPROMOTE: combination therapy shrank soft plaque 28% vs 20% with LDL near 42 vs 70 Louis Nervegna · Oct 31, 2026 · Facebook
  22. FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months Louis Nervegna · Oct 31, 2026 · Facebook
  23. Ezetimibe beyond statins: fewer events, no mortality gain in trials, registry benefits Gokhan Can · Nov 07, 2024 · Facebook
  24. Repatha for 18 months reduced non-calcified plaque on CT angiography in a 47-patient study Louis Nervegna · Mar 02, 2026 · Facebook
  25. PCSK9 inhibitor plus statin nearly halted coronary calcium progression versus statin alone Gokhan Can · Dec 01, 2025 · Facebook
  26. Alirocumab plus statin slowed coronary calcium progression: +2.9% vs +10.6% at 18 months Gokhan Can · Jan 01, 2026 · Facebook
  27. Rosuvastatin lowers LDL slightly more than atorvastatin; LODESTAR outcomes were similar Louis Nervegna · Aug 14, 2026 · Facebook
  28. Limiting diabetes risk on LDL-lowering drugs: statin risk is modest, alternatives exist Gokhan Can · Nov 26, 2025 · Facebook
  29. Statins neither cause nor cure cancer: meta-analyses of randomized trials show no effect Gokhan Can · Dec 31, 2024 · Facebook
  30. Statin RCT meta-analyses show no increase or decrease in cancer risk Louis Nervegna · Dec 31, 2024 · Facebook
  31. Statins activate AMPK via mild mitochondrial stress, which Louis argues is beneficial Louis Nervegna · Nov 23, 2023 · Facebook
  32. Statins do not slow coronary calcium; severe-calcification odds hit 4.48 after 10+ years Gokhan Can · Dec 02, 2025 · Facebook
  33. Calcification paradox: why CAC scores can rise as the heart gets healthier on statins Louis Nervegna · May 01, 2026 · Facebook
  34. AHA's updated high blood pressure definition reflects trials of early treatment Louis Nervegna · Dec 27, 2024 · Facebook
  35. Libby vs Raal debate: is inflammation or LDL the key driver of CVD risk? Gokhan Can · Oct 19, 2024 · Facebook
  36. Statins, especially with ezetimibe, lower Lp-PLA2, a plaque-specific inflammation marker Louis Nervegna · Jun 22, 2025 · Facebook
  37. Tsimikas on why Lp(a) HORIZON missed its endpoint despite strong Lp(a)-risk evidence Louis Nervegna · Sep 05, 2026 · Facebook
  38. Atorvastatin may 'disarm' Lp(a) by blocking oxidation, a theory for HORIZON's failure Louis Nervegna · Nov 10, 2026 · Facebook
  39. GLP-1 agonists cut heart attack risk 14% and CV mortality 13% in a 25-trial meta-analysis Louis Nervegna · Jul 16, 2025 · Facebook
  40. Liver disease plus type 2 diabetes has a multiplicative effect on cardiovascular risk Gokhan Can · Feb 09, 2025 · Facebook
  41. Exercise, including HIIT, can reduce coronary plaque burden and add to LDL lowering Louis Nervegna · Jul 10, 2025 · Facebook
  42. Two years of structured exercise reversed up to 20 years of heart aging at age 50 Louis Nervegna · Mar 18, 2025 · Facebook
  43. DISCO-CT: DASH diet plus statins reversed 39.5 mm3 soft plaque in about a year Louis Nervegna · Apr 22, 2026 · Facebook
  44. CT angiography plaque burden often predicts events better than stenosis severity Louis Nervegna · Jun 09, 2026 · Facebook
  45. Charles Grashow's protocol to regress coronary calcium over two years Gokhan Can · Dec 02, 2023 · Facebook
  46. Low LDL in cancer patients reflects reverse causality: tumours scavenge LDL Louis Nervegna · May 25, 2026 · Facebook
  47. Co-author of LMHR study protocol says the design could not detect plaque progression Louis Nervegna · Dec 10, 2023 · Facebook
  48. Keto-CTA omitted its primary plaque outcome: median NCPV rose 18.8 mm3, 2.5x forecast Louis Nervegna · Apr 13, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary